Drugs in the pipeline may fight MRSA
Infection Control Weekly Monitor, October 29, 2008
Want to receive articles like this one in your inbox? Subscribe to Infection Control Weekly Monitor!
As physicians and other healthcare professionals clamor for drugs that can fight MRSA, two experimental antibiotics appear to work safely against the infections, researchers say.
An experimental antibiotic manufactured by Paratek Phamaceuticals Inc., a Boston company, cleared up MRSA infections in 98 percent of patients treated and had no serious, drug-related adverse events, researchers said at an October 26 news conference as part of a joint meeting of the American Society for Microbiology and the Infectious Diseases Society of America.
The drug, PTK0796, is the first in a new class of drugs called aminomethylcyclines and the company plans to take the medication to phase three trials, the last stage of human testing before seeking U.S. Food and Drug Administration approval, reported Reuters news service.
A Swiss drug company Arpida also announced that its intravenous drug iclaprim cured MRSA infections in 92.3 percent of patients.
Want to receive articles like this one in your inbox? Subscribe to Infection Control Weekly Monitor!
Comments
0 comments on “Drugs in the pipeline may fight MRSA ”
Related Products
-
Patient Safety Monitor
As part of your Patient Safety Monitor membership, you'll receive Briefings on Patient Safety. In this 12-page monthly...
-
Patient Safety Monitor Alert
This e-mail newsletter provides healthcare professionals with the latest patient safety news, while offering useful...
-
Infection Control Weekly Monitor
Infection Control Weekly Monitor keeps you up-to-date on what's happening in the world of infection control. Every issue...
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- QA:Coding multiple initial infusions
- Capturing all necessary codes for IUD insertion and removal can be challenging
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- OB services: Coding inside and outside of the package
- HIPAA Q&A: Level of encryption needed for email
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- What does case-mix index mean to you?
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- Hospitalist-surgeon comanagement has no effect on outcomes
- HIPAA Q&A: Level of encryption needed for email
- Searched